EMRIS Pharma develops a first-in-class topical solution that blocks drug-receptor interactions in the skin to prevent toxicities associated with EGFR inhibitor monoclonal antibodies used in cancer treatment. This approach aims to enhance patients' quality of life and improve adherence to essential cancer therapies by mitigating the severe skin side effects experienced by 80-90% of patients.
Funding
$420K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing cancer treatment with EGFR inhibitor monoclonal antibodies often experience severe skin toxicities, affecting 80-90% of cases. These side effects significantly diminish the patient's quality of life and frequently lead to non-adherence to the prescribed anti-cancer regimen. Current treatments offer limited relief, sometimes necessitating dose reduction or discontinuation of the life-saving anti-cancer drug.
Solution
EMRIS Pharma is developing a topical solution designed to prevent skin toxicities associated with EGFR inhibitors without interfering with the systemic efficacy of the cancer treatment. The solution works by selectively blocking the drug-receptor interaction in the skin, the site of toxicity, thereby mitigating the adverse effects while allowing the anti-cancer drug to continue its therapeutic action. This targeted approach aims to improve patient compliance and quality of life by reducing the need for dose adjustments or treatment cessation. By addressing the skin-related side effects directly, EMRIS Pharma's solution seeks to optimize the overall cancer therapy and potentially enhance patient outcomes.
Target Audience
The primary target audience includes oncologists, dermatologists, and patients undergoing cancer treatment with EGFR inhibitor monoclonal antibodies, particularly those at risk of developing or currently experiencing skin toxicities.
Features
- First-in-class topical formulation designed to prevent EGFRi-induced skin toxicities.
- Selective drug-receptor blockade in the skin to minimize local side effects.
- Does not interfere with the systemic anti-cancer activity of EGFR inhibitors.
- Aims to improve patient adherence to prescribed cancer therapies.
- Designed to enhance the quality of life for patients undergoing cancer treatment.
- PCT patent application filed for skin toxicity prevention and drug delivery.